Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study

Genovese, Mark C., Kaine, Jeffrey L., Lowenstein, Mitchell B., Giudice, José Del, Baldassare, Andrew, Schechtman, Joy, Fudman, Edward, Kohen, Michael, Gujrathi, Sheila, Trapp, Robert G., Sweiss, Nadera J., Spaniolo, Greg, Dummer, Wolfgang, ACTION Study Group · 2008 · Arthritis & Rheumatism

Abstract

Objective: Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, was studied in a first‐in‐human trial in rheumatoid arthritis (RA) patients receiving concomitant methotrexate (MTX). Methods: The ACTION trial was a combined phase I/II study of placebo plus MTX versus ocrelizumab plus MTX in 237 RA patients (intent‐to‐treat population). During phase I, 45 patients were treated with 1 of 5 escalating doses of study drug (infusions on days 1 and 15, 10–1,000 mg per each infusion). An additional 192 patients were randomized during phase II. Eligible patients had active disease, an inadequate response to treatment with at least MTX, rheumatoid factor positivity, and elevated levels of acute‐phase reactants. The total study duration was 72 weeks. B cell pharmacodynamics over time was investigated. Results: Baseline demographics were similar among the treatment groups. Based on the entire 72‐week data set, the incidence of serious adverse events in the ocrelizumab‐treated patients was 17.9%, as compared with 14.6% in placebo‐treated patients. The incidence of serious infections was 2.0% in all ocrelizumab‐treated patients and 4.9% in placebo‐treated patients. Infusion‐associated adverse events were mostly grade 1 or grade 2 and were more frequent around the time of the first infusion. No serious infusion‐associated adverse events were reported in the ocrelizumab group. Evidence of clinical activity was observed at all doses evaluated. Peripheral B cell depletion after infusion was rapid at all doses, with earlier repletion of B cells at doses of 10 mg and 50 mg. Human anti‐human antibodies were detected in 19% and 10%, respectively, of those receiving 10 mg and 50 mg of ocrelizumab, compared with 0–5% of those receiving 200, 500, and 1,000 mg. Conclusion: Ocrelizumab therapy in combination with MTX was well tolerated. Doses of 200 mg (2 infusions) and higher showed better clinical responses, better reduction of C‐reactive protein levels, and very low immunogenicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.23732

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 207

Metadata

Authors
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Giudice, J. D., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R. G., Sweiss, N. J., Spaniolo, G., Dummer, W., & ACTION Study Group
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-08-29
Volume
58
Issue
9
Pages
2652-2661
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2054268831
Cited by
207
References
1
FWCI
16.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study. https://app.cochat.ai/papers/10.1002/art.23732
The paper
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Giudice, J. D., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R. G., Sweiss, N. J., Spaniolo, G., Dummer, W., & ACTION Study Group. (2008). Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study. Arthritis & Rheumatism. https://doi.org/10.1002/art.23732

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.